USD
$0.00
(0.00%
)At Close (As of Sep 17, 2025)
$308.79M
Market Cap
-
P/E Ratio
-5
EPS
$17.48
52 Week High
$7.08
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $81M |
Total Revenue | $229M |
Cost Of Revenue | $147M |
Costof Goods And Services Sold | $147M |
Operating Income | -$92M |
Selling General And Administrative | $73M |
Research And Development | $21M |
Operating Expenses | $173M |
Investment Income Net | - |
Net Interest Income | $13M |
Interest Income | $13M |
Interest Expense | $7K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3M |
Income Before Tax | -$77M |
Income Tax Expense | $5M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$82M |
Comprehensive Income Net Of Tax | - |
Ebit | -$77M |
Ebitda | -$74M |
Net Income | -$82M |
Field | Value (USD) |
---|---|
Total Assets | $685M |
Total Current Assets | $595M |
Cash And Cash Equivalents At Carrying Value | $121M |
Cash And Short Term Investments | $121M |
Inventory | $166M |
Current Net Receivables | $122M |
Total Non Current Assets | $90M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $16M |
Intangible Assets Excluding Goodwill | $16M |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $173M |
Other Current Assets | $13M |
Other Non Current Assets | - |
Total Liabilities | $199M |
Total Current Liabilities | $180M |
Current Accounts Payable | $40M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | - |
Total Non Current Liabilities | $19M |
Capital Lease Obligations | $7.7M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $7.7M |
Other Current Liabilities | $140M |
Other Non Current Liabilities | $12M |
Total Shareholder Equity | $486M |
Treasury Stock | - |
Retained Earnings | -$1.7B |
Common Stock | $305M |
Common Stock Shares Outstanding | $411M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$31M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $3M |
Capital Expenditures | $0 |
Change In Receivables | - |
Change In Inventory | $105M |
Profit Loss | - |
Cashflow From Investment | -$46M |
Cashflow From Financing | -$1.4M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$82M |
Field | Value (USD) |
---|---|
Gross Profit | $81M |
Total Revenue | $229M |
Cost Of Revenue | $147M |
Costof Goods And Services Sold | $147M |
Operating Income | -$92M |
Selling General And Administrative | $73M |
Research And Development | $21M |
Operating Expenses | $173M |
Investment Income Net | - |
Net Interest Income | $13M |
Interest Income | $13M |
Interest Expense | $7K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3M |
Income Before Tax | -$77M |
Income Tax Expense | $5M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$82M |
Comprehensive Income Net Of Tax | - |
Ebit | -$77M |
Ebitda | -$74M |
Net Income | -$82M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Amarin Corporation plc, a pharmaceutical company, is engaged in the development and commercialization of therapies for the treatment of cardiovascular disease in the United States. The company is headquartered in Dublin, Ireland.